Advertisement
Singapore markets close in 2 hours 56 minutes
  • Straits Times Index

    3,172.88
    +0.95 (+0.03%)
     
  • Nikkei

    39,845.97
    +105.57 (+0.27%)
     
  • Hang Seng

    16,563.15
    -173.95 (-1.04%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Bitcoin USD

    65,155.58
    -3,487.91 (-5.08%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • Dow

    38,790.43
    +75.63 (+0.20%)
     
  • Nasdaq

    16,103.45
    +130.25 (+0.82%)
     
  • Gold

    2,160.40
    -3.90 (-0.18%)
     
  • Crude Oil

    82.49
    -0.23 (-0.28%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,550.00
    -3.64 (-0.23%)
     
  • Jakarta Composite Index

    7,344.13
    +41.68 (+0.57%)
     
  • PSE Index

    6,895.97
    +42.68 (+0.62%)
     

Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.